|
|
Santaris Pharma A/S is an international clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies.
The Company’s proprietary Locked Nucleic Acid (LNA) Drug Platform, in combination with its highly specialized and targeted drug development capabilities, offers potential partners pre-screened drug candidates for commercial consideration across a multitude of disease states.
Santaris Pharma A/S research and development activities focus on infectious diseases and metabolic disorders while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, rare genetic disorders and inflammatory diseases.
Santaris Pharma A/S, founded in 2003, is privately-held and headquartered in Denmark with operations in the US. As part of its broad patent estate, the Company holds exclusive worldwide rights to all therapeutic uses of LNAs. The Company has strategic partnerships with Enzon Pharmaceuticals, GlaxoSmithKline, Wyeth Pharmaceuticals (now part of Pfizer) and Shire plc.
|
|
|
|
| |
|
read more about santaris pharma |
|
|
|
|
|
|